This update is a continuation of a series regarding the controversial publication offered through CABI’s Digital Library:

Lyme Disease An Evidence-based Approach 3rd Edition- John Halperin
https://www.cabidigitallibrary.org/doi/book/10.1079/9781800626225.0000

The authors of this publication have been controlling the narrative suppressing all evidence of antibiotic resistance. Previous updates:

Is CABI promoting a false public health narrative? 

Is CABI promoting a false public health narrative? (Part 2)

Is CABI promoting a false public health narrative? (Part 3)

Is CABI promoting a false public health narrative? (Part 4)

---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: Andy Robinson <A.Robinson@cabi.org>
Cc: Damian Bird <D.Bird@cabi.org>
Date: 09/17/2025 9:52 AM EDT
Subject: Johns Hopkins; “Standard antibiotic treatment for Lyme disease does not kill persistent Borrelia bacteria”
 
 
Drs. Robinson and Bird,
 
 
Please see the following comment and peer reviewed research by Dr. Ying Zhang which was coauthored by past IDSA president Paul G Auwaerter.
 
Auwaerter is the lead author of the deplorable Lacent paper: Lyme disease antiscience orchestrating a campaign to discredit the sick and disabled patient population along with the courageous clinicians attempting to help these patients yet the research he coauthored below identifies the reason why Lyme disease persists after antibiotic treatment. Auwaerter is an author of Lyme Disease An Evidence-based Approach 3rd Edition promoted by CABI Digital Library.
 
 
Standard antibiotic treatment for Lyme disease does not kill persistent Borrelia bacteria.
http://droopyyoupi.blogspot.com/2015/08/standart-antibiotic-treatment-for-lyme.html
 
Excerpt:
 
-What has tuberculosis and Borrelia burgdorferi in common? In the late stage of the disease occurs persistent (tolerant) bacteria, which essentially means that the bacteria lasts and lasts and lasts. They protect themselves against antibiotics and are difficult to treat.
 
- Both Borrelia burgdorferi and tuberculosis is relatively easy to cure in the early stages, even with the use of one antibiotic. In the late stage it is impossible to cure the disease with the same type of treatment in the acute phase, said Dr. Ying Zhang when he visited the year NorVect conference.
 
-Dr. Ying Zhang is a professor at the Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health
 
-Two days after NorVect conference, published Dr. Ying Zhang's latest research Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection.
 
 
 
A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library
 
Jie Feng 1, Wanliang Shi 1, Shuo Zhang 1, David Sullivan 1, Paul G Auwaerter 2, Ying Zhang 1
 
https://pubmed.ncbi.nlm.nih.gov/27242757/
 
Abstract
 
Under experimental stress conditions such as starvation or antibiotic exposure, Borrelia burgdorferi can develop round body forms, which are a type of persister bacteria that appear resistant in vitro to customary first-line antibiotics for Lyme disease. To identify more effective drugs with activity against the round body form of B. burgdorferi, we established a round body persister model induced by exposure to amoxicillin (50 μg/ml) and then screened the Food and Drug Administration drug library consisting of 1581 drug compounds and also 22 drug combinations using the SYBR Green I/propidium iodide viability assay. We identified 23 drug candidates that have higher activity against the round bodies of B. burgdorferi than either amoxicillin or doxycycline. 
 
 
 
Carl Tuttle
Independent Researcher
Hudson, NH